SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the appointment of Mark Adams as Vice President of Sales and Marketing. Mr. Adams brings to CryoCor over 20 years of cardiac related medical device sales and marketing experience. He will be responsible for leading CryoCor's commercialization efforts for its Cardiac Cryoablation System, which was approved by the FDA in August 2007 for the treatment of right atrial flutter. CryoCor recently announced the completion of enrollment in its pivotal trial for the treatment of atrial fibrillation, the first company to complete enrollment in a randomized pivotal trial.
Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "I am happy to welcome Mark to CryoCor. Throughout his career, Mark has successfully built and managed sales and marketing teams that have consistently exceeded expectations. We believe that his proven track record, combined with a deep understanding of the cardiac and electrophysiology device markets, will make major contributions as we look to the acceleration of our commercialization efforts and drive adoption of our Cryoablation System. Mark has developed important relationships in the field of electrophysiology that we believe will immediately benefit CryoCor's commercial plans."
Mark Adams, Vice President of Sales and Marketing, commented "I look forward to leading the commercialization efforts for our Cardiac Cryoablation System. I believe this is an important product that meets a significant need in the medical community for the treatment of right atrial flutter and atrial fibrillation. My discussions with physicians have confirmed the thesis that Cryoablation is important in the treatment of these diseases and I look forward to the opportunity to promote and commercialize this product."
Mr. Adams has served at the management and executive levels with several leading electrophysiology companies, including EP Technologies (prior to its acquisition by Boston Scientific), Irvine Biomedical (prior to its acquisition by St. Jude Medical), EP Medsystems and Instromedics, a leader in cardiac event monitoring. Throughout his career, Mr. Adams has been involved in a number of strategic alliance relationships, including with Boston Scientific, Guidant, Medtronic, Phillips and St. Jude Medical. Prior to joining CryoCor, Mr. Adams served as a business consultant providing sales, marketing, operational and staffing expertise to a range of organizations primarily in the medical device industry. Mr. Adams has a long track record of successfully implemented strategic sales and marketing plans.
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary Cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of all supraventricular tachycardias, including atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com.
Forward Looking Statements
The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the pace and success of CryoCor's commercialization activities, Mr. Adams' ability to contribute to those activities, and the potential benefits of and prospects for market adoption of CryoCor's Cardiac Cryoablation System, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks associated with the Company's ability to successfully commercialize its Cryoablation System in the United States and else; risks involved with CryoCor's ability to obtain regulatory approval in the United States for its Cryoablation System for use in treating atrial fibrillation; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.
CryoCor, Inc. The Ruth Group
Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)
Chief Financial Officer (646) 536-7030 / 7020
(858) 909-2200 email@example.com
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved